Evidence map›Paper›PMID 28236004›Full record

ReviewWiener medizinische Wochenschrift (1946)2018

[Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper].

Thomas W Weiss, Miklos Rohla, Benjamin Dieplinger, Hans Domanovits, Dietmar Fries, Milan R Vosko, Thomas Gary, Cihan Ay

Open access · hybridAbstract readReviewConsensus Statement
PubMed Publisher
In one paragraph

Review in Wiener medizinische Wochenschrift (1946), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Thomas W Weiss3. Medizinische Abteilung, Kardiologie und internistische Intensivmedizin, Wilhelminenspital, Montleartstraße 37, 1160 Wien, Österreich. thomas.weiss@meduniwien.ac.at.
Miklos Rohla3. Medizinische Abteilung, Kardiologie und internistische Intensivmedizin, Wilhelminenspital, Montleartstraße 37, 1160 Wien, Österreich.ORCID http://orcid.org/0000-0002-8967-0806
Benjamin DieplingerZentrallabor, Konventhospital Barmherzige Brüder Linz, Seilerstätte 2, 4021, Linz, Österreich.
Hans DomanovitsUniversitätsklinik für Notfallmedizin, Allgemeines Krankenhaus der Stadt Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich.
Dietmar FriesUniv.-Klinik für Allgemeine und Chirurgische Intensivmedizin, Anichstraße 35, 6020, Innsbruck, Österreich.
Milan R VoskoKlinik für Neurologie 2, Med Campus III, Kepler Universitätsklinikum, Krankenhausstr. 9, 4020, Linz, Österreich.
Thomas GaryKlinische Abteilung für Angiologie, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich.
Cihan AyKlinische Abteilung für Hämatologie und Hämostaseologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich.
Convent Hospital of the Brothers of Saint John of God · ATKepler Universitätsklinikum · ATMedical University of Graz · ATSigmund Freud Privatuniversität Wien · ATUniversitätsklinik für Chirurgie Wien · ATVienna General Hospital · ATWilhelminen Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Edoxaban is the most recent available representative of the Non-Vitamin K antagonist oral anticoagulants (NOAC). The approval was based on the largest phase III trials of NOACs for stroke prevention in patients with non-valvular atrial fibrillation (AF, ENGAGE-AF), and for the treatment of venous thromboembolism (VTE, HOKUSAI-VTE). In both trials, edoxaban was associated with similar efficacy and a significant reduction in bleeding events with respect to the pre-defined primary safety endpoints, as compared to warfarin.Additionally, the once daily dosing of edoxaban, the clinically investigated strategy for dose-reduction based on clearly defined criteria and the favorable pharmacokinetic profile might further support the clinical applicability of the substance.In the light of recent data, this expert consensus document aims to summarize the latest clinical trial results while providing a concise overview of current guideline recommendations on the management of patients with non-valvular AF and VTE.

Indexed as

Atrial FibrillationStrokeVenous ThromboembolismAdministration, OralAnticoagulantsFactor Xa InhibitorsHumansPyridinesThiazolesAnticoagulantsedoxabanFactor Xa InhibitorsPyridinesThiazolesAtrial fibrillationEdoxabanNon-Vitamin K antagonist oral anticoagulantsVenous thromboembolism

Identifiers

PMID28236004
OpenAlexW2591486363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.